Semaglutide vs tirzepatide weight loss results differ in how much weight people lose and how the drugs work. Compare doses, side effects, and costs here.
Semaglutide and tirzepatide are both prescription medications approved for chronic weight management in the United States, but they are not identical. Tirzepatide (Zepbound) typically produces greater average weight loss than semaglutide (Wegovy) in clinical trials, while semaglutide has a longer track record and is also available as a pill for diabetes. Both work best alongside a reduced-calorie diet and regular physical activity, and both can cause similar gastrointestinal side effects.
How Semaglutide and Tirzepatide Work
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating, which slows stomach emptying, reduces appetite, and improves blood sugar control. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it targets two hormones instead of one. This dual action is thought to be why tirzepatide often leads to more weight loss.
Neither medication is a stimulant or a fat burner. They change how your body signals hunger and fullness, so you eat less without feeling deprived. That is why they are classified as anti-obesity medications rather than cosmetic shortcuts.
Weight Loss Results: What Clinical Trials Show
Head-to-head data is the best way to compare these drugs. The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in adults with obesity or overweight. Over 72 weeks, tirzepatide produced an average weight loss of about 20.2%, compared with about 13.7% for semaglutide.
Earlier trials told a similar story. In STEP 1, semaglutide 2.4 mg led to roughly 15% average weight loss at 68 weeks. In SURMOUNT-1, tirzepatide 15 mg led to about 21% average weight loss at 72 weeks. Individual results vary widely, and some people lose much more or much less than the average.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Average weight loss | ~15% (STEP 1, 68 weeks) | ~21% (SURMOUNT-1, 72 weeks) |
| Head-to-head result | ~13.7% (SURMOUNT-5) | ~20.2% (SURMOUNT-5) |
| Administration | Weekly injection; oral form for diabetes | Weekly injection |
| Common starting dose | 0.25 mg weekly | 2.5 mg weekly |
| FDA weight loss approval | Yes (Wegovy) | Yes (Zepbound) |
Key conclusion: Tirzepatide produces greater average weight loss than semaglutide in head-to-head clinical trials.
Dosing: Injections vs. Pills
Both drugs are usually started at a low dose and increased slowly to reduce side effects. For semaglutide, the starting dose of semaglutide for weight loss is 0.25 mg once weekly. That dose is not expected to cause much weight loss; it is a tolerance-building step. Your clinician may explain why increase dose of semaglutide for weight loss every four weeks until you reach a maintenance dose, which is typically 1.7 mg or 2.4 mg weekly.
Tirzepatide starts at 2.5 mg weekly and is increased by 2.5 mg every four weeks, up to a maximum of 15 mg weekly. The goal is to find the lowest dose that controls appetite with manageable side effects.
Oral semaglutide is a different story. Rybelsus is an oral GLP-1 pill approved for type 2 diabetes, not for weight loss. The semaglutide tablet dose for weight loss that has been studied is 25 mg daily, which is much higher than the diabetes doses of 3 mg, 7 mg, or 14 mg. As of now, oral semaglutide for weight loss is not FDA-approved, so most people who want semaglutide for weight loss use the weekly injection.
Side Effects and Safety
Semaglutide and tirzepatide share a similar side effect profile. The most common issues are nausea, vomiting, diarrhea, constipation, and stomach pain. These often improve after a few weeks, but they can be severe enough to require a dose reduction or a switch to a different medication.
Rare but serious risks include pancreatitis, gallbladder problems, and bowel obstruction. Both drugs carry a boxed warning about thyroid C-cell tumors seen in rodents, and they are not recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. They are not safe during pregnancy.
Some compounded versions of semaglutide are mixed with vitamin B12. If you are reading reviews of compounded semaglutide with B12, remember that compounded drugs are not FDA-approved and B12 does not increase weight loss. Always talk to a healthcare professional before using any compounded product.
Cost, Insurance, and Availability
List prices are high. Wegovy has a list price around $1,349 per month, and Zepbound around $1,059 per month. Both manufacturers offer savings cards that can lower the cost for people with commercial insurance, and some patients pay $25 to $650 per month depending on coverage.
Medicare Part D does not cover weight loss medications for obesity alone, though it may cover them for certain conditions like sleep apnea or diabetes. Many private insurers require prior authorization, a documented BMI, and proof of diet and exercise efforts before approving coverage.
Which One Is Better for Weight Loss?
When people ask tirzepatide vs semaglutide which is better for weight loss, the honest answer is that tirzepatide has the edge in average weight loss, but "better" depends on your body, your side effects, and what your insurance will cover. Some people lose more weight on semaglutide than expected, and some cannot tolerate tirzepatide at higher doses.
It also helps to separate brand names from drug names. Tirzepatide vs mounjaro for weight loss is a common search, but Mounjaro and Zepbound are the same active ingredient. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight loss. Insurance rules often differ between the two brands even though the drug is identical.
Your clinician can help you choose based on your medical history, current medications, and weight loss goals. No medication works the same for everyone, and neither drug is a cure for obesity. Long-term use is often needed to maintain weight loss.
Key conclusion: Both semaglutide and tirzepatide are effective prescription weight loss medications, but tirzepatide has shown greater average weight loss in direct comparisons.
Key conclusion: Neither semaglutide nor tirzepatide is a replacement for a healthy diet, physical activity, or medical supervision.
Frequently Asked Questions
Which is better for weight loss, semaglutide or tirzepatide?
In a head-to-head trial called SURMOUNT-5, tirzepatide led to about 20.2% average weight loss over 72 weeks, compared with about 13.7% for semaglutide. However, individual results vary, and your doctor may recommend one over the other based on your health history and insurance coverage.
Can I take semaglutide pills for weight loss?
Currently, the FDA-approved form of semaglutide for weight loss is the weekly injection sold as Wegovy. Oral semaglutide (Rybelsus) is approved for type 2 diabetes, not weight loss. A higher-dose oral semaglutide for weight loss is being studied but is not yet available in the US.
What are the most common side effects of semaglutide and tirzepatide?
The most common side effects are nausea, vomiting, diarrhea, constipation, and stomach pain. These usually improve after a few weeks but can be severe. Serious risks include pancreatitis and gallbladder problems, so contact your healthcare provider if you have severe or persistent symptoms.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.